TITLE

Assessment of Heart Rate Variability after Calcium Antagonist and β-Blocker Therapy in Patients with Essential Hypertension

AUTHOR(S)
Rabbia, F.; Martini, G.; Sibona, M.P.; Grosso, T.; Simondi, F.; Chiandussi, L.; Veglio, F.
PUB. DATE
February 1999
SOURCE
Clinical Drug Investigation;1999, Vol. 17 Issue 2, p111
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Objective: Antihypertensive agents of different classes may have profound effects on heart rate variability (HRV). HRV changes in patients with essential hypertension were evaluated after pharmacological treatment by time domain (TD) analysis on 24-hour electrocardiographic (ECG) recordings. Design and Patients: In this randomised block single-blind trial, 45 patients with essential hypertension were randomly assigned to either atenolol, a cardioselective β-blocker, carvedilol, a β-blocker with vasodilator properties, or lacidipine, a long-acting dihydropyridine calcium antagonist, and underwent simultaneous 24-hour ECG and ambulatory blood pressure monitoring before and after 8 weeks' treatment. TD measures were calculated. Results: During treatment with atenolol and carvedilol, the 24-hour average normal RR [mean normal to normal intervals (NN)] was significantly increased (p < 0.0001 and p < 0.0002, respectively). Measures of tonic vagal activity were increased significantly only with atenolol: increase of 64.3% for the percentage of differences >50msec between adjacent NN intervals and increase of 45.2% for root mean square successive differences. By contrast, standard deviations (SD) of all NN over a 24-hour period and SD of means of 5-minute blocks of NN related to total and diurnal HRV were significantly increased by lacidipine (13.4 and 18.9%, respectively) and decreased by carvedilol (-12.0% and -22.0%, respectively) but not significantly modified by atenolol. Modifications in TD parameters were unrelated to the degree of 24-hour blood pressure reduction. Conclusions: HRV, assessed by TD, is modified differently according to the specific type of antihypertensive monotherapy used. These modifications could have prognostic importance. TD measures of HRV may be a practical and powerful instrument for the evaluation of the effect of antihypertensive drugs.
ACCESSION #
9522909

 

Related Articles

  • Beta-Blockers for the Treatment of Essential Hypertension: What are the Arguments Against Their Use as First Line Therapy? Burnier, Michel; Bullani, Roberto; Vogt, Bruno // Current Hypertension Reviews;2007, Vol. 3 Issue 1, p15 

    Beta-blockers are recommended as first line therapy in the treatment of essential hypertension since several decades and this recommendation has been endorsed by most if not all national and international guideline committees. Some concerns about their efficacy in elderly hypertensive patients...

  • Effects of Celiprolol and Bisoprolol on Blood Pressure, Vascular Stiffness, and Baroreflex Sensitivity. Kazuo Eguchi; Satoshi Hoshide; Kazuomi Kario // American Journal of Hypertension;Jul2015, Vol. 28 Issue 7, p858 

    BACKGROUND We tested the hypothesis that celiprolol and bisoprolol have differential effects on blood pressure (BP), flow-mediated dilation (FMD), and vascular stiffness. METHODS We analyzed 102 hypertensives (mean age: 59 ± 14 years) who were being treated other than beta-blockers. They were...

  • Clinical Perspective On The Management Of Hypertension. Iqbal, Muzaffar // Indian Journal of Clinical Medicine;2011, Issue 2, p1 

    Hypertension is an important medical and public health issue all over the world. It is one of the most prevalent conditions seen today by clinicians in both developed and developing countries. Depending upon progression of systolic and diastolic blood pressure it is classified into stage 1, 2...

  • Diltiazem more effective than diuretic/β-blocker in lowering rate of strokes.  // Kidney;Jan/Feb2001, Vol. 10 Issue 1, p24 

    Presents an abstract of the study 'Randomised Trial of Effects of Calcium Antagonists Compared With Diuretics and β-blockers on Cardiovascular Morbidity and Mortality in Hypertension: The Nordic Diltiazem (NORDIL) Study,' by L. Hansson, T. Hedner, P. Lund-Johansen et al.

  • No new hypertension guidance until April.  // GP: General Practitioner;10/14/2005, p7 

    The article reports that a joint NICE and British Hypertension Society (BHS) guideline on the management of hypertension will not be produced for another six months. NICE and the BHS had said they would revise existing guidelines which give conflicting advice over the best treatment for...

  • Antihypertensive medication prescription patterns and time trends for newly-diagnosed uncomplicated hypertension patients in Taiwan. Pang-Hsiang Liu; Jung-Der Wang // BMC Health Services Research;2008, Vol. 8, Special section p1 

    Background: Knowledge of existing prescription patterns in the treatment of newly-diagnosed hypertension can provide useful information for improving clinical practice in this field. The aims of this study are to determine the prescription patterns and time trends for antihypertensive medication...

  • First-Line Treatment for Hypertension. QUYNH BUI // American Family Physician;6/1/2010, Vol. 81 Issue 11, p1333 

    The article examines the case of a 53-year-old healthy woman with persistent hypertension. It compares the effects of thiazide diuretics, beta blockers, angiotensin-converting enzyme (ACE) inhibitors, and calcium channel blockers (CCBs) with placebo. It was found that thiazide diuretics and ACE...

  • The Antihypertensive and Cardiac Hemodynamic Effects of Nebivolol. DeCrée, J.; Van Rooy, P.; Geukens, H.; Haeverans, K.; Verhaegen, H. // Angiology;May1992, Vol. 43 Issue 5, p369 

    Acute, subacute, and chronic treatment with nebivolol, a novel β-selective adrenergic antagonist, significantly lowered systolic and diastolic blood pressure and heart rate in patients with essential hypertension. No orthostatism and bradycardia were reported. A comparison between a normal...

  • β-Blocker use for hypertension may increase CV risk, mortality.  // Reactions Weekly;11/1/2008, Issue 1226, p3 

    This article discusses research being done on the relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension. It references a study by S. Bangalore et. al, published in the October 2008 issue of the "Journal of the American College of Cardiology." A brief overview...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics